We
Think in
Real Time.

We Think in Real Time.

AiM Medical Robotics is a neurosurgical robotics company that is working to bring high levels of precision, automation, and efficiency, to the complex environment of neurosurgery. We are developing a portable MRI compatible surgical robot for use in the MRI Suite and the Operating Room. Our mission is to improve outcomes for patients undergoing neurosurgery for Functional brain disorders (Parkinson’s, Epilepsy, etc) and cancer, while providing cost savings to hospitals by eliminating errors and reducing procedure time by up to 50%.

Team

Leadership Team

gfischer

Gregory Fischer, PhD

CEO/President, Founder & Co-inventor

Julie-Pilitsis

Julie G. Pilitsis, MD, PhD, MBA

Chair of Medical Advisory Board, Founder, and Co-Inventor

John-Gomes

John Gomes

Chief Commercial Officer & Board Member

joe-heanue

Joe Heanue, PhD

Board Member, President and CEO of Triple Ring Technologies

Rachel-LeBlanc

Rachel LeBlanc

Chief Operations Officer & Board Secretary

Jonathan-Sackier

Jonathan Sackier, MB, ChB, FRCS, FACS, DSC

Chief Medical Officer, Board Member

Medical Advisory Board

Sharona-Ben-Haim

Sharona Ben-Haim, MD

Surgical Director of Epilepsy, Associate Professor of Neurological Surgery

David-Charles

David Charles, MD

Professor and Vice-Chair of Neurology

Paul-S-Larson

Paul S. Larson, MD, FAANS

Professor of Neurosurgery at the University of Arizona
Chief of Neurosurgery at the Southern Arizona VA Health Care System<

john-rolston

John Rolston, MD, PhD

Director of Epilepsy Surgery
Director of the Mapping & Engineering Neural Dynamics (MEND) Laboratory
Associate Professor, Harvard Medical School

Jon-Willie

Jon T. Willie, MD, PhD

Director of Stereotactic and Epilepsy Surgery, Department of Neurosurgery, Washington University, St. Louis

Business Advisors

Jon-Willie

Yulun Wang, PhD

Corporate Advisor, Founder and Chairman Computer Motion. Founder and Chairman InTouch Health

Jon-Willie

Samantha Surrey

Business Advisor, Founder of Surrey Capital Partners

Jon-Willie

Scott Davis, PhD

Board Observer, Senior Associate, Life Sciences at Sontag Innovation Fund

Jon-Willie

David Noonan, PhD

Corporate Advisor, Chief Technology Officer at Moon Surgical, Senior Director R+D at Auris Health

Jon-Willie

Alex Wilson

Board Observer, Principal at IQ Capital

Jon-Willie

Andrea Bajo, PhD

Engineering and Development Advisor

Jon-Willie

Sabrina Varanelli

Quality Systems Advisor

Jon-Willie

Dave Saunders

Product Development Advisor

Jon-Willie

Terry Lopaka Adams

Board Observer, Director of Technology Commercialization at WPI

Jon-Willie

Tom Hirschfeld

Board Observer, Board Member, HBS Alumni Angels of NY.

News

AiM Medical Robotics Secures $8.1 Million Series A Financing to Transform Neurosurgery with MRI-Compatible Surgical Robotics

Sep 30, 2025 | READ MORE

AiM Medical Robotics Announces Co-Founder Dr. Julie Pilitsis Elected as President of the American Society for Stereotactic and Functional Neurosurgery

Aug 21, 2024 | READ MORE

AiM Medical Robotics Partners with Brigham and Women’s Hospital for a First Human Clinical Study for MRI-guided Device Placement in the Brain

May 21, 2024 | READ MORE

AiM Medical Robotics Announces Changes to Executive Team and Participation in LSI Emerging Medtech Summit

Mar 08, 2023 | READ MORE

AiM Medical Robotics Unveils Prototype of MRI-Compatible Intraoperative Robot for Neurosurgery and Receives Funding from Sontag Foundation Innovation Fund

Aug 22, 2022 | READ MORE

AiM Medical Robotics Raises $3.4M in Seed Financing to Advance Neurosurgery with MRI-Compatible Robotics

Mar 15, 2022 | READ MORE

AiM Medical Robotics Appoints Dr. Jonathan M. Sackier as Chief Medical Officer

Mar 03, 2022 | READ MORE

AiM Medical Robotics Appoints Dr. Gregory Cole as Chief Technology Officer

Feb 17, 2022 | READ MORE

AiM Medical Robotics to Host Panel Discussion and Present at Biofuture™

Sep 30, 2021 | READ MORE

AiM Medical Robotics Appoints Dr. Babak Kateb to Medical Advisory Board

Jul 29, 2021 | READ MORE

AiM Medical Robotics to Present and Exhibit at 18th Annual World Congress of Society for Brain Mapping and Therapeutics (SBMT)

Jul 07, 2021 | READ MORE

AiM Medical Robotics Appoints Jonathan Sackier to the Board of Directors

May 11, 2021 | READ MORE

Media

Contact

If you would like to contact us, please complete the form below.
We will reply as soon as possible.

Investors

AiM Medical Robotics is an early stage growth company supported by a number of funds including IQ Capital and Surrey Capital Partners.  For more information, please email us at ir@aimmedrobotics.com.

This device is investigational and not approved by the FDA

Forward-Looking Statement
This website includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. These statements are based on AiM’s current expectations, estimates, and projections about our industry, our business, and the device we are developing; and are subject to substantial risks, uncertainties and assumptions. The statements concern AiM’s business strategies; research and development plans; the timing of regulatory submissions; the ability to obtain and maintain regulatory authorizations of AiM’s products; market acceptance of AiM’s products; AiM’s intellectual property; AiM’s reliance on third party organizations; AiM’s competitive position; AiM’s industry environment; AiM’s anticipated financial and operating results, including anticipated sources of revenues; AiM’s assumptions regarding the size of the available market, the benefits of AiM’s products; product pricing and timing of product launches; management’s expectation with respect to future acquisitions; AiM’s goals, intentions, plans and expectations, including the introduction of new products and markets; and AiM’s cash needs and financing plans. Actual events may differ materially from the expectations indicated by such forward-looking statements. You should not place undue reliance on these forward-looking statements, which can be identified by words such as “could,” “believe,” “anticipate,” “intend,” “believe,” “estimate,” “expect,” “may,” “will,” “could,” “continue,” “predict,” “potential,” “project” or similar terms, variations of such terms or the negative of those terms. Our medical device is currently in development and remains subject to significant risks and uncertainties, including, but not limited to, delays or difficulties in preclinical and clinical testing, obtaining required regulatory authorizations, supply chain and/or manufacturing challenges, changes in market conditions, and potential competition. The timing and outcome of regulatory reviews and clinical trial results are inherently uncertain and could adversely affect the commercial viability of our product. AiM may not realize its expectations or achieve its plans. Actual results may differ materially from those indicated by these forward-looking statements as a result of various factors, including those described in our filings with the Securities and Exchange Commission (SEC), such as risk factors contained in our most recent Annual Report on Form 10-K. All forward-looking statements reflect current beliefs and assumptions of AiM management as of the date of this [document/press release]. Consequently, forward-looking statements should be regarded solely as AiM’s current plans, estimates, and beliefs. AiM cannot guarantee future results, events, or performance. AiM does not undertake and specifically declines any obligation to update or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.